Vectorite Biomedical

Vectorite Biomedical P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is -105.55. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -53.05 — a change of 98.96% (lower).

P/CF

-105.55

YoY

98.96%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Vectorite Biomedical is 2025 -105.55 . P/CF (Price-to-Cash-Flow Ratio) of Vectorite Biomedical was 2024 -53.05 . It decreases by 98.96% lower compared to the previous year.

The Vectorite Biomedical P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-7.16 TWD
Jan 1, 2019
-9.74 TWD
Jan 1, 2020
-16.55 TWD
Jan 1, 2021
-9.28 TWD
Jan 1, 2022
41.53 TWD
Jan 1, 2023
470.42 TWD
Jan 1, 2024
-53.05 TWD
Jan 1, 2025
-105.55 TWD
The Vectorite Biomedical P/CF history
YEARP/CFYoY
-105.55+98.96%
-53.05-111.28%
470.42+1,032.67%
41.53-547.51%
-9.28-43.91%
-16.55+69.97%
-9.74+35.98%
-7.16-140.51%
17.67-252.66%
-11.58-70.91%
-39.80+160.32%
-15.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

P/CF (Price-to-Cash-Flow Ratio) of Vectorite Biomedical is -105.55 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Vectorite Biomedical changed from -53.05 to -105.55, representing a 98.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Vectorite Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Vectorite Biomedical

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Vectorite Biomedical